Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Semmler

Showing results (171-180 of 196) with videos related to

Pageof 20
Sort By:
Hepatology (Baltimore, Md.)|July 14, 2020
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver DiseaseGeorg Semmler, Teresa Binter, Karin Kozbial, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 18, 2025
Prevalence of Fibrosis and Applicability of Lab-based Noninvasive Tests From Primary to Tertiary CareGeorg Semmler, Paul Thöne, Jan Embacher, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2026
Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular riskConstanze Hoebinger, Georg Semmler, Oleksandr Petrenko, et al.
Wiener Klinische Wochenschrift|October 17, 2025
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease : Austrian Society of Gastroenterology and Hepatology (ÖGGH), Austrian Society of Diabetology (ÖDG), Austrian Society of Obesity (ÖAG)Mattias Mandorfer, Georg Semmler, Elmar Aigner, et al.
Alimentary Pharmacology & Therapeutics|August 11, 2025
MetALD: Diagnosis and Prognosis With Non-Invasive TestsNikolaj Torp, Mads Israelsen, Stine Johansen, et al.
Gastroenterology|December 22, 2025
Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver DiseaseNikolaj Torp, Stine Johansen, Ellen Lyngbeck Jensen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 14, 2026
Fibrosis progression rate and comparison of paired liver biopsy versus non-invasive tests as surrogate endpoints for clinical trials in MetALD and ALDEllen Lyngbeck Jensen, Maja Thiele, Nikolaj Torp, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2025
Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosisLorenz Balcar, Malin Fromme, Naomi Kappe, et al.
Wiener Klinische Wochenschrift|June 26, 2023
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)Mattias Mandorfer, Elmar Aigner, Manfred Cejna, et al.
Journal of Hepatology|December 6, 2021
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver diseaseGeorg Semmler, Elias Laurin Meyer, Karin Kozbial, et al.
Pageof 20

Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
Hepatology (Baltimore, Md.)|July 14, 2020
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver DiseaseGeorg Semmler, Teresa Binter, Karin Kozbial, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 18, 2025
Prevalence of Fibrosis and Applicability of Lab-based Noninvasive Tests From Primary to Tertiary CareGeorg Semmler, Paul Thöne, Jan Embacher, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2026
Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular riskConstanze Hoebinger, Georg Semmler, Oleksandr Petrenko, et al.
Wiener Klinische Wochenschrift|October 17, 2025
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease : Austrian Society of Gastroenterology and Hepatology (ÖGGH), Austrian Society of Diabetology (ÖDG), Austrian Society of Obesity (ÖAG)Mattias Mandorfer, Georg Semmler, Elmar Aigner, et al.
Alimentary Pharmacology & Therapeutics|August 11, 2025
MetALD: Diagnosis and Prognosis With Non-Invasive TestsNikolaj Torp, Mads Israelsen, Stine Johansen, et al.
Gastroenterology|December 22, 2025
Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver DiseaseNikolaj Torp, Stine Johansen, Ellen Lyngbeck Jensen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 14, 2026
Fibrosis progression rate and comparison of paired liver biopsy versus non-invasive tests as surrogate endpoints for clinical trials in MetALD and ALDEllen Lyngbeck Jensen, Maja Thiele, Nikolaj Torp, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2025
Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosisLorenz Balcar, Malin Fromme, Naomi Kappe, et al.
Wiener Klinische Wochenschrift|June 26, 2023
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)Mattias Mandorfer, Elmar Aigner, Manfred Cejna, et al.
Journal of Hepatology|December 6, 2021
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver diseaseGeorg Semmler, Elias Laurin Meyer, Karin Kozbial, et al.
Pageof 20